Podcasts about cme

Charlie is an internationally renowned consultant, practitioner, author, speaker, and trainer, of Lean and Agile improvements spanning over 4 decades. Charlie has published 20 books to date, in healthcare, manufacturing, and a children's book and received two Shingo Prizes. Seven of the books have been translated into other languages. There are more in the works. Charlie spent over 13 years with AlliedSignal (now Honeywell) and has been implementing TQM/ Lean Principles and Thinking since 1985. He was the first TQM/Lean Master and a Strategic Operations Manager for AlliedSignal where he received several special recognition and cost reduction awards. Charlie is an external consultant for the Maryland World Class Consortia (MWCC) and a co-author for the resulting World Class Guidelines in 1998. He has been a keynote speaker for the MWCC, Chinese Industrial Engineering Institute, China's Benchmark Lean conferences, and Agile DEVOPS conference in Portugal and done several Lean/ Agile podcasts to date. He has put on training seminars for The Dark Report's Quality Confab and Executive War College.Charlie started Business Improvement Group (BIG) in 1997, and along with his son and other partners, spent the last 28 years implementing successful Lean Implementations and World Class Kaizen events for small to fortune 100 companies across the U.S., Canada, Mexico, Puerto Rico, Europe and Asia. He has taught Lean Thinking Principles to students from all over the world.Charlie is following in the footsteps of his grandfather, Charles W. Protzman, Sr. who, as part of the CCS, under the direction of MacArthur in 1949-50, along with Homer Sarasohn, taught CEO's of over 50 prominent Japanese Telecommunications Companies an eight-week course in American Industrial Management. It was Protzman and Sarasohn that then recommended Deming to JUSE, to continue their quality teachings leading to Deming's 8-day Quality Course starting in 1950 and creation of the Deming Prize.Charlie has a BA and MBA from Loyola University in Maryland.Link to claim CME credit: https://www.surveymonkey.com/r/3DXCFW3CME credit is available for up to 3 years after the stated release dateContact CEOD@bmhcc.org if you have any questions about claiming credit.

“They say it takes a village to raise a child. I really think it takes a village to treat a patient,” says Dr. Lanae Mullane, a naturopathic doctor and clinical strategist who has spent years at the forefront of bridging functional medicine, nutraceutical development, and digital health. In this episode of Raise the Line, host Lindsey Smith explores Dr. Mullane's view that naturopathic medicine complements conventional care by expanding -- not replacing -- the clinical toolkit, and that collaboration should be the future of medicine. “At the end of the day, collaboration and connection create the best outcomes for the people we serve,” she says. Their in-depth conversation also spans the shifting landscape of women's hormone health, including the perimenopausal transition and long-overdue calls for research equity. “We're not just smaller versions of men. We need to have dedicated research for us.” Tune in to learn about the importance of grounding health in sustainable habits, rethinking midlife care for women, and how to help patients take ownership of their health.Mentioned in this episode:Joi + BlokesSuppCoDr. Mullane's Clinical Website If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Featuring an interview from Dr John Strickler, including the following topics: Prognostic value of molecular residual disease (MRD) as detected by circulating tumor DNA (ctDNA) and optimal incorporation of MRD assays into the care of patients with colorectal cancer (0:00) Potential use of MRD assays for patients with microsatellite instability (MSI)-high localized colorectal cancer or those with delayed progression or metastatic disease (16:09) Tumor-informed MRD assays under clinical development (20:36) Predictive role of ctDNA in Stage III colon cancer treated with celecoxib; effect of low-dose aspirin on response to celecoxib in patients with PI3K pathway alterations (24:19) Case: A man in his late 50s with resected Stage IIA colon cancer (30:06) Case: A woman in her late 40s with Lynch syndrome and MSI-H colon cancer with a solitary, small hepatic metastasis (34:57) MRD as a future clinical trial endpoint for solid tumors; increasing incidence of colorectal cancer in younger people (40:24) Antibody-drug conjugates in the treatment of colorectal cancer (45:13) Perspectives on promising areas of clinical research in colorectal cancer (48:23) CME information and select publications

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/GPQ865. CME credit will be available until November 3, 2026.Making Connections to Improve Patient Care in Obesity, Metabolism, and Liver Health In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Obesity Medicine Association. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

Dr John Strickler from Duke University in Durham, North Carolina, discusses the measurement of molecular residual disease and its current and potential role in colorectal cancer risk assessment, surveillance and treatment decision-making. CME information and select publications here.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/GPQ865. CME credit will be available until November 3, 2026.Making Connections to Improve Patient Care in Obesity, Metabolism, and Liver Health In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Obesity Medicine Association. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

Dr John Strickler from Duke University in Durham, North Carolina, discusses the measurement of molecular residual disease and its current and potential role in colorectal cancer risk assessment, surveillance and treatment decision-making. CME information and select publications here.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/GPQ865. CME credit will be available until November 3, 2026.Making Connections to Improve Patient Care in Obesity, Metabolism, and Liver Health In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Obesity Medicine Association. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/GPQ865. CME credit will be available until November 3, 2026.Making Connections to Improve Patient Care in Obesity, Metabolism, and Liver Health In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Obesity Medicine Association. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/GPQ865. CME credit will be available until November 3, 2026.Making Connections to Improve Patient Care in Obesity, Metabolism, and Liver Health In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Obesity Medicine Association. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

Dr John Strickler from Duke University in Durham, North Carolina, discusses the measurement of molecular residual disease and its current and potential role in colorectal cancer risk assessment, surveillance and treatment decision-making. CME information and select publications here.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/GPQ865. CME credit will be available until November 3, 2026.Making Connections to Improve Patient Care in Obesity, Metabolism, and Liver Health In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Obesity Medicine Association. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

Featuring a slide presentation and related discussion from Dr John Strickler, including the following topics: Defining molecular residual disease (MRD); tumor-informed and tumor-naïve methods for assessing (0:00) GALAXY and BESPOKE CRC studies of a tumor-informed MRD assay to identify patients with localized colorectal cancer who have an increased risk of recurrence and those who are likely to benefit from adjuvant chemotherapy (6:56) Sustained circulating tumor DNA (ctDNA) clearance and disease-free survival outcomes for patients with localized colorectal cancer (13:21) DYNAMIC study of a ctDNA-guided approach to adjuvant chemotherapy for patients with Stage II colorectal cancer (16:17) ctDNA positivity and radiographic evidence of colorectal cancer (18:48) ctDNA-guided approaches to escalating or de-escalating adjuvant chemotherapy for patients with localized colorectal cancer (21:24) Predictive role of ctDNA assay results in Stage III colon cancer treated with celecoxib; low-dose aspirin for patients with Stage II to III colorectal cancer with a PI3K pathway alteration (26:02) CME information and select publications

This episode is sponsored by Lightstone Direct LLC. Lightstone DIRECT invites you to partner with a $12B AUM real estate institution as you grow your portfolio. Access the same single-asset multifamily and industrial deals Lightstone pursues with its own capital – Lightstone co-invests a minimum of 20% in each deal alongside individual investors like you. You're an institution. Time to invest like one.____________________________________________________________________Struggling to differentiate sinus symptoms? You're not alone—medical training often falls short.In this solo episode of Succeed in Medicine, Dr. Bradley Block shares how to distinguish between colds, bacterial sinusitis, allergies, and sinus migraines. With insights from years of clinical experience, on sinusitis as a secondary bacterial infection following viruses, not allergies or blockages. He covers "second sickness" patterns, why 10-day watchful waiting beats early antibiotics, migraine misdiagnoses, and treatments like nasal steroids for allergies versus surgery for fungal balls. Debunking myths like balloon sinuplasty for migraines. This episode equips physicians with practical tools to avoid overtreatment and improve patient outcomes, learn why facial pressure often points to migraines, when antibiotics are truly needed, and how to spot the “second sickness” pattern of sinus infections. Packed with practical tips and myth-busting, this episode is a must-listen for anyone navigating sinus issues or curious about ENT care.Three Actionable Takeaway:Sinusitis Starts with a Virus: Dr. Block explains bacterial sinusitis as a secondary infection after a cold disrupts sinus mucosa—watch for "second sickness" where symptoms worsen after initial improvement. Hold antibiotics for at least 10 days unless complications like orbital cellulitis arise.Facial Pressure Isn't Always Sinus: Often misdiagnosed as sinusitis, facial pressure (especially weather-related) signals migraines—Dr. Block advises checking for tenderness over sinuses and avoiding unnecessary CT scans or surgery like balloon sinuplasty, which treats mucosa issues poorly.Allergies vs. Sinusitis: Separate Issues: Allergies swell nasal mucosa but don't cause sinus infections due to insufficient allergen entry—treat with nasal steroids or immunotherapy. Fungal balls require surgery, not meds, as they're not true infections. About the Show:Succeed In Medicine  covers patient interactions, burnout, career growth, personal finance, and more. If you're tired of dull medical lectures, tune in for real-world lessons we should have learned in med school!About the Host:Dr. Bradley Block – Dr. Bradley Block is a board-certified otolaryngologist at ENT and Allergy Associates in Garden City, NY. He specializes in adult and pediatric ENT, with interests in sinusitis and obstructive sleep apnea. Dr. Block also hosts Succeed In Medicine podcast, focusing on personal and professional development for physiciansWant to be a guest?Email Brad at brad@physiciansguidetodoctoring.com  or visit www.physiciansguidetodoctoring.com to learn more!Socials:@physiciansguidetodoctoring on Facebook@physicianguidetodoctoring on YouTube@physiciansguide on Instagram and Twitter This medical podcast is your physician mentor to fill the gaps in your medical education. We cover physician soft skills, charting, interpersonal skills, doctor finance, doctor mental health, medical decisions, physician parenting, physician executive skills, navigating your doctor career, and medical professional development. This is critical CME for physicians, but without the credits (yet). A proud founding member of the Doctor Podcast Network!Visit www.physiciansguidetodoctoring.com to connect, dive deeper, and keep the conversation going. Let's grow! Disclaimer:This podcast is for informational purposes only and is not a substitute for professional medical, financial, or legal advice. Always consult a qualified professional for personalized guidance. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

“It's kind of a miracle, frankly,” says Dr. John Buse, a distinguished professor at the University of North Carolina School of Medicine, referring to the effectiveness of GLP-1 receptor agonist medications such as Ozempic in treating type 2 diabetes, promoting significant weight loss, and reducing cardiovascular risk. As a physician scientist for the last three decades at UNC, Dr. Buse has played a key role in ushering in this new era of diabetes care, leading or participating in over 200 clinical studies on this class of drugs and others. “Nothing has impacted diabetes care like the GLP-1 receptor agonists. I have lots of patients whose diabetes was never well controlled who have seen all their metabolic problems essentially resolved.”  In this fascinating conversation with Raise the Line host Lindsey Smith, Dr. Buse not only explains how these drugs work, but also provides a clear-eyed look at side effects, and addresses issues of cost and access. Join us for the remarkable story – including the role played by Gila monsters -- behind one of the biggest developments in medicine over the past several years from a world renowned diabetes researcher and clinician. Mentioned in this episode:UNC School of Medicine If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

How can we get ourselves out of the current political situation?What is the political industrial complex?In this series on healthcare and social disparities, Dr. Jill Wener, a board-certified Internal Medicine specialist, anti-racism educator, meditation expert, and tapping practitioner, interviews experts and gives her own insights into multiple fields relating to social justice and anti-racism. In this episode, Jill interviews Eva Posner, an award-winning political consultant. They elaborated on the importance of making politics people-driven rather than money-driven and resources to support local campaigns that make real change in our country. Eva opened Evinco Strategies in 2016 to focus on electing candidates who increase representation in government — specializing in first-time candidates from diverse backgrounds who face barriers in traditional campaigns, as well as issue campaigns that tackle systemic injustice.Eva is passionate about social and criminal justice, local and state-level campaigns, diverse representation in politics, and training the next generation of political operatives. Prior to her work in politics, Eva worked as a journalist, with a focus on government and human trafficking. She earned her bachelor's degree in journalism from the University of Tennessee.LINKSwww.evincostrategies.com**Our website www.consciousantiracism.comYou can learn more about Dr. Wener and her online meditation and tapping courses at www.jillwener.com, and you can learn more about her online social justice course, Conscious Anti Racism: Tools for Self-Discovery, Accountability, and Meaningful Change at https://theresttechnique.com/courses/conscious-anti-racism.If you're a healthcare worker looking for a CME-accredited course, check out Conscious Anti-Racism: Tools for Self-Discovery, Accountability, and Meaningful Change in Healthcare at www.theresttechnique.com/courses/conscious-anti-racism-healthcareJoin her Conscious Anti-Racism facebook group: www.facebook.com/groups/307196473283408Follow her on:Instagram at jillwenerMDLinkedIn at jillwenermd

Lucy Kalanithi, MD, FACP, Clinical Associate Professor of Medicine, Stanford University, San Jose, CaliforniaCME Credit Available for all Providence ProvidersIn order to claim CME credit, please click on the following link: ⁠⁠⁠ https://forms.office.com/r/0jJWjWBjY1 (or copy & paste into your browser)Accreditation Statement: Providence Oregon Region designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1  creditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Providence Oregon Region is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.Planning Committee & Faculty Disclosure: The planning committee and faculty have indicated no relevant financial relationships with an ACCME-defined ineligible company. Their planning contributions were evidence-based and unbiased. All financial relationships (if any) have been mitigated.Original Date: October 28, 2025End Date: October 28, 2026

Lucy Kalanithi, MD, FACP, Clinical Associate Professor of Medicine, Stanford University, San Jose, CaliforniaCME Credit Available for all Providence ProvidersIn order to claim CME credit, please click on the following link: ⁠⁠⁠ https://forms.office.com/r/0jJWjWBjY1 (or copy & paste into your browser)Accreditation Statement: Providence Oregon Region designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1  creditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Providence Oregon Region is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.Planning Committee & Faculty Disclosure: The planning committee and faculty have indicated no relevant financial relationships with an ACCME-defined ineligible company. Their planning contributions were evidence-based and unbiased. All financial relationships (if any) have been mitigated.Original Date: October 28, 2025End Date: October 28, 2026

In episode 65 we discuss varenicline and bupropion for alcohol use disorder.  Söderpalm B, Lidö H, Franck J, Håkansson A, Lindqvist D, Heilig M, Guterstam J, Samuelson M, Askerup B, Wallmark-Nilsson C, de Bejczy A. Efficacy and safety of varenicline and bupropion, in combination and alone, for alcohol use disorder: a randomized, double-blind, placebo-controlled multicentre trial. Lancet Reg Health Eur. 2025 May 13;54:101310.     We also discuss medical marijuana for anxiety in Pennsylvania, and RFK's embrace of psychedelic therapy.  Annals of Internal Medicine: Medical Cannabis Certifications After Pennsylvania Added Anxiety Disorders as a Qualifying Condition  Annals of Internal Medicine: High-Concentration Delta-9-Tetrahydrocannabinol Cannabis Products and Mental Health Outcomes: A Systematic Review  MedPageToday: Will RFK Jr.'s Push for Psychedelic Therapy Help or Hamper the Emerging Field?  ---  This podcast offers category 1 and MATE-ACT CME credits through MI CARES and Michigan State University. To get credit for this episode and others, go to this link to make your account, take a brief quiz, and claim your credit. To learn more about opportunities in addiction medicine, visit MI CARES.  CME: https://micaresed.org/courses/podcast-addiction-medicine-journal-club/   ---  Original theme music: composed and performed by Benjamin Kennedy  Audio editing: Michael Bonanno  Executive producer: Dr. Patrick Beeman  A podcast from Ars Longa Media  ---  This is Addiction Medicine Journal Club with Dr. Sonya Del Tredici and Dr. John Keenan. We practice addiction medicine and primary care, and we believe that addiction is a disease that can be treated. This podcast reviews current articles to help you stay up to date with research that you can use in your addiction medicine practice.   ---  The best part of any journal club is the conversation. Send us your comments on social media or join our Facebook group.  Email: addictionmedicinejournalclub@gmail.com   Facebook: @AddictionMedJC  Facebook Group: Addiction Medicine Journal Club  Instagram: @AddictionMedJC   Threads: @AddictionMedJC  YouTube: addictionmedicinejournalclub   Twitter/X: @AddictionMedJC    ---  Addiction Medicine Journal Club is intended for educational purposes only and should not be considered medical advice. The views expressed here are our own and do not necessarily reflect those of our employers or the authors of the articles we review. All patient information has been modified to protect their identities. Learn more about your ad choices. Visit megaphone.fm/adchoices

Kevin Kalinsky from Winship Cancer Institute of Emory University in Atlanta, Georgia, discusses recent developments with TROP2-directed antibody-drug conjugates in the management of breast cancer. CME information and select publications here.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/JYH865. CME credit will be available until October 20, 2026.The Earlier the Better in Lung Cancer: Multispecialty Guidance on Screening, Diagnosis and Management of Resectable NSCLC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/JYH865. CME credit will be available until October 20, 2026.The Earlier the Better in Lung Cancer: Multispecialty Guidance on Screening, Diagnosis and Management of Resectable NSCLC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/JYH865. CME credit will be available until October 20, 2026.The Earlier the Better in Lung Cancer: Multispecialty Guidance on Screening, Diagnosis and Management of Resectable NSCLC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/JYH865. CME credit will be available until October 20, 2026.The Earlier the Better in Lung Cancer: Multispecialty Guidance on Screening, Diagnosis and Management of Resectable NSCLC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/JYH865. CME credit will be available until October 20, 2026.The Earlier the Better in Lung Cancer: Multispecialty Guidance on Screening, Diagnosis and Management of Resectable NSCLC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.Disclosure information is available at the beginning of the video presentation.

What do you get when a top New York news anchor, a journalist, and a perimenopausal powerhouse writes a book? You get How to Menopause — a no-BS guide to midlife, straight from someone who lived it, confused, anxious, and totally unsupported. In this episode, I sit down with my friend and author Tamsen Fadal to talk about what it was like to unknowingly navigate perimenopause during a high-profile career, the moment she literally hit the bathroom floor, and why she turned her personal chaos into a mission to educate others. We talk hormones, misdiagnoses, pelvic floor surprises, brain fog on live TV, and why body composition matters now. Oh, and yes — she verbed “menopause.” This one's raw, real, funny, and totally relatable. Whether you're in the middle of it or still wondering what the hell is going on, this episode (and her book) is for you.

Former paramedic and has been an ER physician for 7-8 yearsHe pursued emergency medicine after his experience as a paramedic because he feels it is more in line with his personality We talk about how emergency medicine checks a lot of exciting boxes that we enjoyAdam talks about his burnout symptoms as well as how he course-correctsHe talks about symptoms like lacking as much compassion/empathy as he should have. So he corrects by talking with his wife, focuses on getting enough sleep etcHe has let go, to some degree, of all the “techniques” we learn to combat burnout and refocused on his “why” – he knows his purpose. He was called by God to do this job“Without question, I was called to be in this position by God – it changes everything”Part of the difficulty of the ER is the sheer volume of people we see on a given day, in a lot of ways, we are managing a lot of mental health conditions in that volume – it can be an opportunity and a gift rather than just viewing it as something to get through. Seeing people as human beingsThis perspective can help us avoid cynicism – I've found that assuming good intentions on the part of everyone I encounter during the day goes a long way towards avoiding cynicism and taking better care of patientsWe must intentionally hold on to the victories, the grateful patient, the lifesaving situation When you look for the good, you tend to find itWe talk about setting tone for the rest of the staff in the EDWe talk faith in emergency medicine as Christians, it has everything to do with everything that we do in life and in the job“I would have chosen an easier job with an easier route to get to it if it wasn't for God”“The hope I have in Jesus sustains me”Why do awful things happen to good peopleFree will leads to the world we see and proves that we are not God, yet we are called to His standardThe potential of every human to do self-seeking, evil is why we see some of the horrible things we see, the answer is where do we take these burdensI discuss my view of free will and its ramifications and our mission on earth as Christians“Should only bring patience and kindness and hope to an interaction with another human who is suffering” Support the showEverything you hear today from myself and my guests is opinion only and doesn't represent any organizations or companies that any of us are affiliated with. The stories you hear have been modified to protect patient privacy and any resemblance to real individuals is coincidental. This is for educational and entertainment purposes only and should not be taken as medical advice nor used to diagnose any medical or healthcare conditions. This is not medical advice. If you have personal health concerns, please seek professional care. Full show notes can be found here: Episodes - Practical EMS - Content for EMTs, PAs, ParamedicsMost efficient online EKG course here: Practical EKG Interpretation - Practical EMS earn 4 CME and learn the fundamentals through advanced EKG interpretation in under 4 hours. If you want to work on your nutrition, increase your energy, improve your physical and mental health, I highly recommend 1st Phorm. Check them out here so they know I sent you. 1st Phorm | The Foundation of High Performance Nutrition

HOST: Mark Longo, The Options Insider Media Group CME HOT SEAT: Giovanni Vicioso, Global Head of Cryptocurrency Products at CME Group In this episode, the discussion covers CME's recent launch of Solana and XRP options, the role of institutional and retail participants, and the evolution of use cases for Bitcoin and Ether futures and options. The episode also highlights plans for 24/7 trading in CME's crypto suite starting in early 2026, pending regulatory approval. Additionally, the episode features a dive into the Movers and Shakers report, showcasing significant moves in the energy and metals sectors.  

HOST: Mark Longo, The Options Insider Media Group CME HOT SEAT: Giovanni Vicioso, Global Head of Cryptocurrency Products at CME Group In this episode, the discussion covers CME's recent launch of Solana and XRP options, the role of institutional and retail participants, and the evolution of use cases for Bitcoin and Ether futures and options. The episode also highlights plans for 24/7 trading in CME's crypto suite starting in early 2026, pending regulatory approval. Additionally, the episode features a dive into the Movers and Shakers report, showcasing significant moves in the energy and metals sectors.  

Link for CME credit coming soon! Dr. Avinash Boddapati joins Pediatrics Now and builds on the wonderful talk by Dr. Mario Fierro in part one, to explain more about what we know—and don't—about the causes of autism, highlighting that autism is multifactorial and involves genetics, brain biology, and environmental influences. He covers early red flags, genetic risk and testing, maternal and prenatal factors, common misconceptions (including vaccines), and promising research directions like gene–environment interactions and epigenetics. Key takeaways for pediatric clinicians: counsel families without blame, prioritize early identification and intervention, and weigh risks and benefits when discussing exposures during pregnancy.

Feeling like your paycheck is your only safety net? It's time to change that. In this episode, Tracy Bingaman—PA, career coach, and your go-to brainstorming buddy—shares practical and creative ways to diversify your income as a clinician.From investing beyond retirement to medical surveys, teaching, consulting, and creative work like medical writing or coaching PA applicants, Tracy walks you through both active and passive income ideas that can help you build security and freedom.

Morgan started his career as a fitter turner and raised up through the rank to officer in theNavy. Morgan has over 30 years' experience in Lean and 25 years in Six Sigma, apragmatic and experienced improvement Leader, delivering over $2.21Bn in hard savings toorganization, improving customer, staff experiences and improved Health and Safety. Thelegacy capabilities of Business Improvement have resulted in over 23 international awards, 3literary awards and chairing 27 international conferences around Business Improvement andTransformation. Morgan has led an organization to be the first bank to a Shingo award andsupported a mining site in Chile to Shingo Prize. He is also a Chartered Engineer, CertifiedMaster Black Belt, Lean Master, and Executive Coach. Morgan has leadership experience inmarine, manufacturing, government, military, mining, utilities, telecommunications, oil andgas, banking, and supply chain.Regarded as a thought leader in behavioural transformation and a highly regarded coachwith challenging the status quo and developing new thinking.Link to claim CME credit: https://www.surveymonkey.com/r/3DXCFW3CME credit is available for up to 3 years after the stated release dateContact CEOD@bmhcc.org if you have any questions about claiming credit.

Did you know that congenital heart defects (CHDs) affect nearly 40,000 babies born in the United States every year? On this episode, Pediatric Cardiologist Dr. Melissa Lefebvre and medical student Marina Hashim discuss the evaluation and management of common acyanotic congenital heart conditions. Specifically, they will: Review the classification of CHDs as cyanotic versus acyanotic. Discuss the pathophysiology of the three most common acyanotic CHDs – ASD, PDA, and VSD. Describe early clinical findings and use of diagnostic tools. Cover management options, ranging from spontaneous closure to surgical intervention. Explore prognosis and long-term outcomes on physical activity, neurodevelopment, and overall health. Special thanks to Dr. Rebecca Yang and Dr. Abeer Hamdy for peer reviewing this episode. CME available free with sign up: Link Coming Soon! References: Dimopoulos, K., Constantine, A., Clift, P., & Condliffe, R. (2023). Cardiovascular complications of down syndrome: Scoping review and expert consensus. Circulation, 147(5). https://doi.org/10.1161/CIRCULATIONAHA.122.059706   Dugdale, D. C. (Ed.). (n.d.). Pediatric heart surgery - discharge. Mount Sinai. Retrieved April 26, 2024, from https://www.mountsinai.org/health-library/discharge-instructions/pediatric-heart-surgery-discharge   Eckerström, F., Nyboe, C., Maagaard, M., Redington, A., & Hjortdal, V. (2023). Survival of patients with congenital ventricular septal defect. European Heart Journal,  44 (1,1), 54-61. https://doi.org/10.1093/eurheartj/ehac618   Heart MRI. (2022, July 24). Cleveland Clinic. Retrieved April 19, 2024, from https://my.clevelandclinic.org/health/diagnostics/21961-heart-mri Leihao, S., Yajiao, L., Yunwu, Z., Yusha, T., Yucheng, C., & Lei, C. (2023). Heart-brain axis: Association of congenital heart abnormality and brain diseases. Frontiers in Cardiovascular Medicine, 10. https://doi.org/10.3389/fcvm.2023.1071820 Meyer, K. (Ed.). (2022, May 1). What is a ventricular septal defect (VSD)? Cincinnati Children's. Retrieved March 12, 2024, from https://www.cincinnatichildrens.org/health/v/vsd Minette, M. S., & Sahn, D. S. (2006). Ventricular septal defects. Circulation, 114(20). https://doi.org/10.1161/CIRCULATIONAHA.106.618124 Mussatto, K. A., Hoffmann, R. G., Hoffman, G. M., Tweddell, J. S., Bear, L., Cao, Y., & Brosig, C. (2014). Risk and prevalence of developmental delay in young children with congenital heart disease. Pediatrics, 133(3), e570–e577. https://doi.org/10.1542/peds.2013-2309 Pruthi, S. (Ed.). (2022, October 21). Ventricular septal defect (VSD). Mayo Clinic. Retrieved April 9, 2024, from https://www.mayoclinic.org/diseases-conditions/ventricular-septal-defect/symptoms-causes/syc-20353495     Right heart catheterization. (2022, July 24). Cleveland Clinic. Retrieved April 19, 2024, from https://my.clevelandclinic.org/health/diagnostics/21045-right-heart-catheterization Shah, S., Mohanty, S., Karande, T., Maheshwari, S., Kulkarni, S., & Saxena, A. (2022). Guidelines for physical activity in children with heart disease. Annals of pediatric cardiology, 15(5-6), 467–488. https://doi.org/10.4103/apc.apc_73_22 Sigmon, E., Kellman, M., Susi, A., Nylund, C., & Oster, M. (2019). Congenital heart disease and Autism: A case-control study. Pediatrics, 144(5). https://doi.org/10.1542/peds.2018-4114 Thacker, D. (Ed.). (2022, January 1). Ventricular septal defect (VSD). Nemours Kids Health. Retrieved April 10, 2024, from https://kidshealth.org/en/parents/vsd.html   Tierney, S., & Seda, E. (2020). The benefit of exercise in children with congenital heart disease. Current Opinion in Pediatrics, 32(5), 626-632. https://doi.org/10.1097/MOP.0000000000000942  Ventricular septal defects (VSD). (2021, November 9). Cleveland Clinic. Retrieved April 2, 2024,from https://my.clevelandclinic.org/health/diseases/17615-ventricular-septal-defects-vsd    Ventricular septal defect surgery for children. (n.d.). Johns Hopkins Medicine. Retrieved April 11,2024, from https://www.hopkinsmedicine.org/health/treatment-tests-and-therapies/ventricular-septal-defect-surgery-for-children#:~:text=During%20this%20surgery%2C%20a%20surgeon,the%20hole%20between%20the%20ventricles Wernovsky, G., & Licht, D. J. (2016). Neurodevelopmental Outcomes in children with congenital heart disease - what can we impact?. Pediatric Critical Care Medicine: a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies, 17(8 Suppl 1), S232–S242. https://doi.org/10.1097/PCC.0000000000000800

“It wasn't a profession, it was a way of life,” observes internationally respected psychiatrist Dr. Nasser Loza, reflecting on a century-long family legacy in mental health care that began when his grandfather founded The Behman Hospital in Cairo. In this candid Raise the Line conversation with host Michael Carrese, Dr. Loza traces the transformation of psychiatry he's witnessed in his long career as increases in classifications, payment bureaucracy, reliance on pharmaceuticals, and technological disruption have each left their mark. The cumulative costs associated with these changes have, he laments, pushed care out of reach for many and hindered the human connection that is key to the discipline. He describes his prescription for countering these trends as a focus on effective and modest aims. “Rather than saying, come and see me in therapy for five years and I will make a better person out of you, I think focusing on symptom-targeted help is going to be what is needed.”  In this wide-ranging interview, you'll also learn about progress on advancing the rights of mental health patients and lowering stigmas, how to manage the rise of online therapy and use of AI chatbots, and the importance of empathy and transparency in mental health counseling. Don't miss this valuable perspective on a critically important dimension of healthcare that's informed by decades of experience as a clinician, government official and global advocate. Mentioned in this episode:The Behman HospitalMaadi Psychology Center If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Featuring an interview with Dr Eunice S Wang, including the following topics: Hypomethylating agent/venetoclax combinations for the treatment of acute myeloid leukemia (AML); integration in community practice (0:00) All-oral regimen of decitabine/cedazuridine with venetoclax for patients with newly diagnosed AML not eligible for intensive induction chemotherapy (9:39) Efficacy of targeted therapy options for AML; potential role of MRD (minimal residual disease) assays in monitoring treatment response (13:07) Treatment approach for patients with FLT3-mutant AML; mutation profiles and predicting response to quizartinib (20:14) Targeting the differentiation of AML tumor cells with IDH and menin inhibitors; associated differentiation syndrome (29:24) Efficacy and tolerability of the IDH inhibitors ivosidenib and olutasidenib (36:54) Key clinical data with approved and investigational menin inhibitors for AML; current and potential integration of menin inhibitors in the AML treatment algorithm (42:30) CME information and select publications

Dr Eunice S Wang from Roswell Park Comprehensive Cancer Center in Buffalo, New York, discusses recent datasets and their implications for the current and future management of acute myeloid leukemia. CME information and select publications here.

Welcome to Perimenopause WTF!, brought to you by ⁠Perry⁠—the #1 perimenopause app and safe space for connection, support, and new friendships during the menopause transition. You're not crazy, and you're not alone!  Download the free Perry App on ⁠Apple⁠ or ⁠Android⁠ and join our live expert talks, receive evidence-based education, connect with other women, and simplify your perimenopause journey.Today's episode is titled “The Perimenopause Wake-Up Call: How to Rise, Roar, and Rewrite Midlife”. Authors Shannon Watts & Jen Hatmaker sit down for a deeply personal and revealing conversation as they open up about their individual experiences navigating perimenopause. They candidly discuss the confusing symptoms, the challenge of self-discovery, and the treatments and lifestyle changes that ultimately brought them clarity and relief. 

Episode Summary In this special Tick Boot Camp Podcast episode, Dr. Myriah Hinchey (ND) joins Matt Sabatello and Rich Johannesen from Tick Boot Camp to spotlight the 2025 LymeBytes Symposium, a physician- and patient-focused conference designed to shorten the healing journey for Lyme, mold illness, PANS/PANDAS, Long COVID, and other complex, infection-driven chronic conditions. We dig into why immersive learning accelerates progress, how an intimate format fuels direct access to top clinicians and vendors, and what attendees—both in-person and virtual—will actually experience over two packed days in Fort Lauderdale. Exclusive Listener Offer: Use code TBC100 at checkout for $100 off in-person or virtual tickets at shop.lymebytes.com. Why This Episode Matters End the isolation: Dr. Hinchey explains how community, validation, and shared learning unlock momentum for both patients and clinicians. Immersion = speed: Concentrated exposure to leading experts and technologies helps you discover the next best step faster. Bridging the gap: Learn why precision care often requires a team—LLMDs, specialty labs, compounders, targeted supplements, and therapeutic devices—working together. What You'll Learn Inside the LymeBytes philosophy: Healthy, gluten- and dairy-free meals, beach-side community dinner, structured networking, and vendor access that mirror the lifestyle principles used in treatment. Adjunctive therapies on site: Demos and education around hyperbaric oxygen therapy (OxyHealth), infrared/red light, Relax Sauna, Therasage, plus niche supplement brands (e.g., Alight by Dr. Jill Crista, NutraMedix, Lymecore Botanicals) and specialty labs for Lyme, co-infections, and mold. Precision testing & interpretation: Why test results (e.g., Western Blots, specialty panels) must be read in clinical context, and how collaboration between vendors and clinicians personalizes care. PRP/TruDose spotlight: A primer on platelet-rich plasma (PRP) and how TruDose aims to reset immune function and calm the nervous system using your own platelets—plus a teaser for a future deep-dive episode. Virtual experience (no FOMO): Live access to all clinician lectures, slides, full-day recordings to rewatch/scrub, and new vendor mini-interviews so remote attendees don't miss the expo value. Who Should Attend the Symposium Patients & caregivers seeking credible, actionable strategies to shorten recovery time Clinicians (conventional, integrative, functional) looking to upgrade protocols for chronic infection and inflammation Allies & advocates ready to learn the truth about Lyme and related conditions from top voices in the field Anyone who wants direct access to vendors, labs, and tools that often stay off patients' radars Event Details (In-Person + Virtual) Dates: November 14–15, 2025 Location: Fort Lauderdale Marriott Pompano Beach Resort & Spa (Florida) Format: Limited-capacity, intimate event (≈180–200 attendees) fostering direct interaction with clinicians, researchers, and vendors Perks: Healthy meals (GF/DF), Friday night beach dinner, curated vendor hall, 14.5 CME credits available in person (additional fee) Virtual: Live stream + full-day recordings (Day 1 & Day 2), slide access, vendor mini-features Register: shop.lymebytes.com $100 Off: Use code TBC100 at checkout (in-person or virtual) Notable Quotes On immersion: “The more volume of opportunities in an immersive environment, the more your internal diagnostic system can sense what resonates—and that's often your next right step.” On community: “Patients and clinicians are often dismissed or isolated. This event builds real connections you can rely on after you go home.” On precision: “Chronic cases are outliers—they need specialized testing, targeted supplements, and coordinated care to get unstuck.” Call to Action If travel isn't possible, don't wait—join virtually to access the same lectures, slides, and full-day recordings. And if you can make it to Florida, come say hi to Rich and the Tick Boot Camp crew in person.

Featuring a slide presentation and related discussion from Dr Eunice S Wang, including the following topics: All-oral regimen of decitabine/cedazuridine with venetoclax for patients with newly diagnosed acute myeloid leukemia (AML) not eligible for intensive induction chemotherapy (0:00) Quizartinib-based treatment approaches for FLT3-ITD-mutated and FLT3-ITD wild-type AML (5:21) First- and second-generation IDH inhibitors for AML (17:40) Updated results from the AUGMENT-101 Phase II study of the menin inhibitor revumenib for relapsed/refractory KMT2A-rearranged AML (22:59) Phase Ib/II KOMET-001 study of ziftomenib for relapsed/refractory NMP1-mutant AML (26:42) Novel combination approaches with menin inhibitors for AML (29:11) CME information and select publications

What if the work that feels invisible is the very thing building your expertise?For many CME writers, the hours spent researching, editing, and shaping educational content happen behind the scenes — valuable, but unseen. Over time, that invisibility can blur your sense of value and readiness.In this Write Medicine hot-seat coaching session, Gina Castiblanco PhD shares what it's really like to navigate that in-between space — leaving behind a visible academic identity and learning to trust her voice as a CME writer and business owner.Together, we unpack how professional visibility starts with self-awareness, boundaries, and the courage to say, “I'm ready, even if I don't feel ready yet.”By the end of this conversation, you'll learn how to:Reframe invisibility as part of your growth process — not proof that you don't belong.Use your academic and clinical background to shape a distinct CME writing identity.Turn your unseen skills into visible value that attracts aligned clients and projects.Shift from doing the work to owning the work — as a creative, strategic partner.Stay to the end of the episode for three practical steps you can take today to start making your invisible work visible — and strengthen your visibility, voice, and value in the CME ecosystem.Mentioned in this episode:Alliance AlmanacThis podcast uses the following third-party services for analysis: Podtrac - https://analytics.podtrac.com/privacy-policy-gdrp

Limb-girdle muscular dystrophies (LGMDs) encompass a group of genetically heterogeneous skeletal muscle disorders. There has been an explosion of newly identified LGMD subtypes in the past decade, and results from preclinical studies and early-stage clinical trials of genetic therapies are promising for future disease-specific treatments. In this episode, Gordon Smith, MD, FAAN, speaks with Teerin Liewluck, MD, FAAN, FANA, author of the article “Limb-Girdle Muscular Dystrophies” in the Continuum® October 2025 Muscle and Neuromuscular Junction Disorders issue. Dr. Smith is a Continuum® Audio interviewer and a professor and chair of neurology at Kenneth and Dianne Wright Distinguished Chair in Clinical and Translational Research at Virginia Commonwealth University in Richmond, Virginia. Dr. Liewluck is a professor of neurology at the Division of Neuromuscular Medicine and Muscle Pathology Laboratory at Mayo Clinic College of Medicine in Rochester, Minnesota. Additional Resources Read the article: Limb-Girdle Muscular Dystrophies Subscribe to Continuum®: shop.lww.com/Continuum Earn CME (available only to AAN members): continpub.com/AudioCME Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Host: @gordonsmithMD Guest: @TLiewluck Full episode transcript available here Dr Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum. Thank you for listening to Continuum Audio. Be sure to visit the links in the episode notes for information about earning CME, subscribing to the journal, and exclusive access to interviews not featured on the podcast. Dr Smith: This is Dr Gordon Smith with Continuum Audio. Today I'm interviewing Dr Teerin Liewluck, a good friend of mine at the Mayo Clinic, about his article on the limb girdle muscular dystrophies. This article appears in the October 2025 Continuum issue on muscle and neuromuscular junction disorders, a topic that is near and dear to my heart. Teerin, welcome to the podcast, and maybe you can introduce yourself to our listeners. Dr Liewluck: Thank you very much, Gordon, and I want to say hi to all the Continuum fans. So, I'm Dr Teerin Liewluck, I'm the professor of neurology at Mayo Clinic in Rochester, Minnesota. So, my practice focus on all aspects of muscle diseases, both acquired and genetic myopathies. Glad to be here. Dr Smith: I just had the great pleasure of seeing you at a seminar in Houston where you talked about this topic. And so, I'm really primed for this conversation, which I'm very excited about. I find this topic a little hard, and I'm hoping I can learn more from you. And I wonder if, as we get started, recognizing many of our listeners are not in practices focused purely on muscle disease, maybe you can provide some context about why this is important for folks doing general neurology or even general neuromuscular medicine? Why do they need to know about this? Dr Liewluck: Yes, certainly. So, I would say limb girdle muscular dystrophy probably the most complex category of subgroup of muscle diseases because, by itself, it includes thirty-four different subtypes, and the number's still expanding. So, each subtype is very rare. But if you group together, it really have significant number of patients, and these patients present with proximal weakness, very high CK, and these are common patients that can show up in the neurology clinic. So, I think it's very important even for general neurologists to pick up what subtle clues that may lead to the diagnosis because if we are able to provide correct diagnosis for the patients, that's very important for patient management. Dr Smith: So, I wonder if maybe we can talk a little bit about the phenotype, Terran. I mean, your article does a great job of going over the great diversity. And you know, I think many of us here, you know, limb girdle muscular dystrophy and we think of limb girdle weakness, but the phenotypic spectrum is bananas, right? Rhabdomyolysis, limb girdle distal myopathy. I mean, when should our listeners suspect LGMD? Dr Liewluck: Yes, I think by the definition to all the LGMD patients will have limb girdle of proximal weakness and very high CK. So, these are common phenotypes among thirty-four different subtypes. But if it did take into details, they have some subtle differences. In the article, what I try to simplify all these different subtypes that we can categorize at least half of them into three main group that each group the underlying defect sharing among those subtypes and also translate into similar muscles and extra muscular manifestations. You will learn that some of the limb girdle muscular dystrophy may present with rhabdomyolysis. And we typically think of this as metabolic myopathies. But if you have a rhabdomyolysis patient, the CK remain elevated even after the acute episode, that's the key that we need to think this could be LGMD. That's for an example. Dr Smith: So, I wonder if maybe we can start there. I was going to go in a different direction, but this is a good transition. It's easy to see the opportunity to get confused between LGMD or, in that case, a metabolic myopathy or other acquired myopathies. And I think particularly adult neurologists are more accustomed to seeing acquired muscle disease. Are there particular clues that, or pearls that adult neurologists seeing patients with muscle disease can use to recognize when they should be thinking about LGMD given the diverse phenotype? Dr Liewluck: Yes. What I always tell the patient is that there are more than a hundred different types of muscle diseases, but we can easily divide into groups: acquired and genetic or hereditary. So, the acquired disease is when you encounter the patients who present with acute or subacute cause of the weakness, relatively rapidly progressive. But on the opposite, if you encounter the patient who present with a much more slowly progressive cause of weakness over several months or years, you may need to think about genetic disease of the muscle with also including limb-girdle muscular dystrophy. The detailed exam to be able to distinguish between each type of muscular dystrophy. For example, if proximal weakness, certainly limb girdle muscular dystrophy. If a patient has facial weakness, scapular winking, so you would think about facial scapular hematoma dystrophy. So, the slowly progressive cause of weakness, proximal pattern of weakness, CK elevation, should be the point when you think about LGMD. Dr Smith: So, I have a question about diagnostic evaluation. I had a meeting with one of my colleagues, Qihua Fan, who's a great peripheral nerve expert, who also does neuromuscular pathology. And we were talking about how the pathology field has changed so much over the last ten years, and we're doing obviously fewer muscle biopsies. Our way of diagnosing them has changed a lot with the evolution of genetic testing. What's your diagnostic approach? Do you go right to genetic testing? Do you do targeted testing based on phenotype? What words of wisdom do you have there? Dr Liewluck: Yes, so, I mean, being a muscle pathologist myself, it is fair to say that the utility of muscle biopsies when you encounter a patient with suspects that limb girdle muscular dystrophy have reduced over the year. For example, we used to have like fifteen, seventeen hundred muscle biopsies a year; now we do only thirteen hundred biopsies a year. Yes, as you pointed out, the first step in my practice if I suspect LGMD is to go with genetic testing. And I would prefer the last gene panel that not only include the LGMD, but also include all other genetic muscle disease as well as the conjunctive myopic syndrome, because the phenotype can be somehow difficult to distinguish in certain patients. Dr Smith: So, do you ever get a muscle biopsy, Teerin? I mean you obviously do; only thirteen hundred. Holy cow, that's a lot. So, let me reframe my question. When do you get a muscle biopsy in these patients? Dr Liewluck: Muscle biopsy still is present in LGMD patients, it's just we don't use it at the first-tier diagnostic test anymore. So, we typically do it in selected cases after the genetic testing in those that came back inconclusive. As you know, you may run into the variant of unknown significance. You may use the muscle biopsy to see, is there any histopathology or abnormal protein Western blot that may further support the heterogenicity of the VUS. So, we still do it, but it typically comes after genetic testing and only in the selected cases that have inconclusive results or negative genetic testing. Dr Smith: I'd like to ask a question regarding serologic testing for autoantibodies. I refer to a really great case in your article. There are several of them, but this is a patient, a FKRP patient, who was originally thought to have dermatomyositis based on a low-titer ME2 antibody. You guys figured out the correct diagnosis. We send a lot of antibody panels out. Wonder if you have any wisdom, pearls, pitfalls, for how to interpret antibody tests in patients with chronic myopathies? We send a lot of them. And that's the sort of population where we need to be thinking about limb-girdle muscular dystrophies. It's a great case for those, which I hope is everyone who read your article in detail. What do you have to say about that? Dr Liewluck: Yes, so myositis antibodies, we already revolutionized a few of muscle diseases. I recall when I finished my fellowship thirteen years ago, so we don't really have much muscle myositis antibodies to check. But now the panel is expanded. But again, the antibodies alone cannot lead to diagnosis. You need to go back to your clinical. You need to make sure the clinical antibodies findings are matched. For example, if the key that- if the myocytes specific antibodies present only at the low positive title, it's more often to be false positive. So, you need to look carefully back in the patient, the group of phenotypes, and when in doubt we need to do muscle biopsies. Now on the opposite end, the other group of the antibody is the one for necrotizing autoimmune myopathy; or, the other name, immune-mediated necrotizing myopathy. This is the new group that we have learned only just recently that some patients may present as a typical presentation. I mean, when even thinking about the whole testing autoimmune myopathy, we think about those that present with some acute rapidly progressive weakness, maybe has history of sudden exposures. But we have some patients that present with very slowly progressive weakness like muscular dystrophies. So now in my practice, if I encounter a patient I suspect LGMD, in addition to doing genetic testing for LGMD, I also test for necrotizing doing with myopathy antibodies at the same time. And we typically get antibody back within what, a week or two, but projected testing would take a few months. Dr Smith: Yeah. And I guess maybe you could talk a little bit about pitfalls and interpretation of genetic tests, right? I think you have another case in your article, and I've certainly seen this, where a patient is misdiagnosed as having a genetic myopathy, LGMD, based on, let's say, just a misinterpretation of the genetic testing, right? So, I think we need to think of it on both sides. And I like the fact that the clinical aspects of diagnosis really are first and foremost most important. But maybe you can talk about wisdom in terms of interpretation of the genetic panel?  Dr Liewluck:Yes. So genetic testing, I think, is a complex issue, particularly for interpretation. And if you're not familiar with this, it's probably best to have your colleagues in genetics that help looking at this together. So, I think the common scenario we encounter is that in those dystrophies that are autosomal recessive, so we expect that the patient needs to have two abnormal copies of the genes to cause the disease. And if patients have only one abnormal copy, they are just a carrier. And commonly we see patients refer to us as much as dystrophy is by having only one abnormal copy. If they are a carrier, they should not have the weakness from that gene abnormality. So, this would be the principle that we really need to adhere. And if you run into those cases, then maybe you need to broaden your differential diagnosis. Dr Smith: I want to go back to the clinical phenomenology, and I've got a admission to make to you, Teerin. And I find it really hard to keep track of these disorders at, you know, thirty-four and climbing a lot of overlap, and it's hard to remember them. And I'm glad that I'm now going to have a Continuum article I can go to and look at the really great tables to sort things out. I'm curious whether you have all these top of mind? Do you have to look at the table too? And how should people who are seeing these patients organize their thoughts about it? I mean, is it important that you memorize all thirty-four plus disorders? How can you group them? What's your overall approach to that? Dr Liewluck: I need to admit that I've not memorize all twenty-four different subtypes, but I think what I triy to do even in my real-life practice is group it all together if you can. For example, I think that the biggest group of these LGMD is what we call alpha-dystroglycanopathies. So, this include already ten different subtypes of recessive LGMD. So alpha-dystroglycan is the core of the dystrophin-associated glycoprotein complex. And it's heavy glycosylated protein. So, the effect in ten different genes can affect the glycosylation or the process of adding sugar chain to this alpha-dystroglycan. And they have similar features in terms of the phenotype. They present with proximal weakness, calf pseudohypertrophy, very high CK, some may have recurrent rhabdomyolysis, and cardiac and rhythmic involvement are very common. This is one major group. Now the second group is the limb-girdle muscular dystrophy due to defective membrane repair, which includes two subtypes is the different and on dopamine five. The common feature in this group is that the weakness can be asymmetric and despite proximal weakness, they can have calf atrophy. On muscle biopsy sometimes you can see a myeloid on the muscle tissues. And the third group is the sarcoglycanopathy, which includes four different subtypes, and the presentation can look like we share. For the rest, sometimes go back to the table. Dr Smith: Thank you for that. And it prompts another question that I always wonder about. Do you have any theories about why such variability in the muscle groups that are involved? I mean, you just brought up dystroglycanopathy, for instance, as something that can cause a very distal predominant myopathy; others do not. Do we at this point now have an understanding given the better genetics that we have on this and work going on in therapeutic development, which I want to get to in a minute, that provides any insight why certain muscle groups are more affected? Dr Liewluck: Very good question, Gordon. And I would say the first question that led me interested in muscle disease---and this happened probably back in 2000 when I just finished medical school---is why, why, why? Why does muscle disease tend to affect proximal muscles? I thought by now, twenty-five years later, we'd have the answer. I don't. I think this, you don't know clearly why muscle diseases, some affect proximal, some affect distal. But the hypothesis is, and probably my personal hypothesis is, that maybe certain proteins may express more in certain muscles and that may affect different phenotypes. But, I mean, dysferlin has very good examples that can confuse us because some patients present with distal weakness, some patients present with proximal weakness, that's by the same gene defect. And in this patient, when we look at the MRI in detail, actually the patterns of fatty replacements in muscle are the same. Even patient who present clinically as a proximal or distal weakness, the imaging studies show the same finding. Bottom line, we don't know. Dr Smith: Yeah, who knew it could be so complex? Teerin, you brought up a really great point that I wanted to ask about, which is muscle MRI scan, right? We're now seeing studies that are doing very broad MR imaging. Do you use some muscle MRI very frequently in your clinical evaluation of these patients? And if so, how? Dr Liewluck: Maybe I don't use it as much as I could, but the most common scenario I use in this setting is when I have the genetic testing come back with the VUS. So, we look at each VUS, each gene in detail. And if anything is suspicious, what I do typically go back to the literature to see if that gene defect in particular has any common pattern of muscle involvement on the MRI. And if there is, I use MRI as one of the two to try to see if I can escalate the pathogenicity of that VUS. Dr Smith: And a VUS is a “Variant of Unknown Significance,” for our listeners. I'm proud that I remember that as a geneticist. These are exciting times in neurology in general, but particularly in an inherited muscle disease. And we're seeing a lot of therapeutic development, a lot going on in Duchenne now. What's the latest in terms of disease-modifying therapeutics and gene therapies in LGMD? Dr Liewluck: Yes. So, there are several precritical and early-phase critical trials for gene therapy for the common lymphoma of muscular dystrophies. For example, the sarcoglycanopathies, and they also have some biochemical therapy that arepossible for the LGMD to FKRP. But there are many things that I expect probably will come into the picture broader or later phase of critical tryouts, and hopefully we have something to offer for the patients similar to patients with Duchenne muscular dystrophy. Dr Smith: What haven't we talked about, I mean, holy cow? There's so much in your article. What's one thing we haven't talked about that our listeners need to hear? Dr Liewluck: Good questions. So, I think we covered all, but often we get patients with proximal weakness and high CK, and they all got labeled as having limb-girdlemuscular dystrophy. What I want to stress is that proximal weakness and high CK is a common feature for muscle diseases, so they need to think broad, need to think about all possibilities. Particularly don't want to miss something treatable. Chronic, slowly progressive cause, as I mentioned earlier, we think more about muscle dystrophy, but at the cranial range, we know that rare patients with necrotic autonomyopathy and present with limb good of weakness at a slowly progressive cost. So, make sure you think about these two when suspecting that LGMD patient diabetic testing has come back inconclusive. Dr Smith: Well, that's very helpful. And fortunately, there's several other articles in this issue of Continuum that help people think through this issue more broadly. Teerin, you certainly don't disappoint. I enjoyed listening to you about a month ago, and I enjoyed reading your article a great deal and enjoy talking to you even more. Thank you very much. Dr Liewluck: Thank you very much, Gordon. Dr Smith: Again, today I've been interviewing Dr Teerin Liewluck about his article on limb-girdle muscular dystrophy, which appears in the October 2025 Continuum issue on muscle and neuromuscular junction disorders. Please be sure to check out Continuum Audio episodes for this and other issues. And thanks to our listeners for joining today. Dr Monteith: This is Dr Teshamae Monteith, Associate Editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practitioners. Use the link in the episode notes to learn more and subscribe. AAN members, you can get CME for listening to this interview by completing the evaluation at continpub.com/audioCME. Thank you for listening to Continuum Audio.

This episode is sponsored by Lightstone Direct LLC. Lightstone Direct LLC connects you to institutional-quality real estate investments backed by a $12-billion AUM firm that co-invests alongside you—your partner in building lasting wealth. All investments involve risk. Please visit LightstoneDirect.com for a full list of disclosures.__________________________________________________Can improv skills transform patient interactions in healthcare?Dr. Bradley Block and Tane Danger, share how improvisation fosters essential skills like active listening, empathy, collaboration, and adaptability. Drawing from over 20 years in improv theater, Tane explains techniques such as "Yes, And" to validate patient concerns and build trust, staying present to avoid jumping to conclusions, and using nonverbal cues for better rapport. Through fun exercises like one-word stories, Tane demonstrates how these tools help healthcare professionals slow down, connect authentically, and navigate unpredictable situations, ultimately making interactions more enjoyable and effective for both providers and patients.Three Actionable Takeaways:· Stay Present and Listen Actively: In healthcare, it's easy to jump to conclusions based on experience, but staying present ensures accurate diagnoses and builds patient trust. Repeat the last thing a patient says to start your response, slowing down your thought process, demonstrating engagement, and allowing their full story to unfold naturally for better outcomes. Embrace "Yes, And": Validate patient ideas by starting responses with "Yes" to affirm what they've said, then add "And" to build collaboratively, exploring their concerns without dismissal. This fosters open dialogue, rapport, and partnership, turning potential conflicts into constructive conversations that enhance understanding and adherence to treatment plans. Incorporate Theatricality: Use exaggerated nonverbal cues, like expressive facial reactions and body language, to show genuine interest in patients' stories. This "theatricality" amplifies empathy, making interactions more authentic and helping patients feel heard, even if you're familiar with their condition, ultimately strengthening trust and the therapeutic relationship. About the ShowSucceed In Medicine  covers patient interactions, burnout, career growth, personal finance, and more. If you're tired of dull medical lectures, tune in for real-world lessons we should have learned in med school!About the Guest:Tane Danger is an improviser with over 20 years of experience performing, teaching, and directing improv theater. He is the co-founder of Danger Boat Productions, which uses improv to facilitate important conversations and improve communication and collaboration. As artist-in-residence at the Mayo Clinic Lavin Center for Humanities in Medicine, he trains healthcare professionals in improv techniques to enhance connection, empathy, and quick thinking.  Website: tanedanger.comCompany Website: dangerboat.netAbout the Host:Dr. Bradley Block – Dr. Bradley Block is a board-certified otolaryngologist at ENT and Allergy Associates in Garden City, NY. He specializes in adult and pediatric ENT, with interests in sinusitis and obstructive sleep apnea. Dr. Block also hosts Succeed In Medicine podcast, focusing on personal and professional development for physiciansWant to be a guest?Email Brad at brad@physiciansguidetodoctoring.com  or visit www.physiciansguidetodoctoring.com to learn more!Socials:@physiciansguidetodoctoring on Facebook@physicianguidetodoctoring on YouTube@physiciansguide on Instagram and Twitter This medical podcast is your physician mentor to fill the gaps in your medical education. We cover physician soft skills, charting, interpersonal skills, doctor finance, doctor mental health, medical decisions, physician parenting, physician executive skills, navigating your doctor career, and medical professional development. This is critical CME for physicians, but without the credits (yet). A proud founding member of the Doctor Podcast Network!Visit www.physiciansguidetodoctoring.com to connect, dive deeper, and keep the conversation going. Let's grow! Disclaimer:This podcast is for informational purposes only and is not a substitute for professional medical, financial, or legal advice. Always consult a qualified professional for personalized guidance. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

“When I was in medical school, no one had even heard of mitochondrial disease. Today, every student who graduates here knows what it is and has seen a patient with it,” says Dr. Mary Kay Koenig, director of the Center for the Treatment of Pediatric Neurodegenerative Disease at UTHealth Houston McGovern Medical School. That remarkable change in awareness has been accompanied by advances in genetic sequencing, the development of clinical guidelines, and the emergence of potential treatments in some forms of mitochondrial disease. In fact, Dr. Koenig's multidisciplinary team at UTHealth's Mitochondrial Center of Excellence has been a key player in clinical trials that may yield the first FDA-approved treatments for it. As you'll learn in this Year of the Zebra conversation with host Michael Carrese, her work in neurodegenerative diseases also includes tuberous sclerosis, where advanced therapies have replaced the need for repeated surgeries, and Leigh Syndrome, which has seen improvements in diagnoses and supportive therapies leading to better quality of life for patients.  Tune in as Dr. Koenig reflects on an era of progress in the space, the rewards of balancing research, teaching and patient care, and the need for more clinicians to center listening, humility and honesty in their approach to caring for rare disease patients and their  families.Mentioned in this episode:Mitochondrial Center of ExcellenceCenter for the Treatment of Pediatric Neurodegenerative Disease If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Featuring perspectives from Dr Aditya Bardia and Dr Adam M Brufsky, including the following topics: Introduction: Antibody-drug conjugates in localized breast cancer (0:00) Case: A frail woman in her late 70s with ER-positive, HER2-low metastatic breast cancer (mBC) receives sacituzumab govitecan after multiple lines of therapy — Eric Fox, DO (7:46) Case: A woman in her early 60s with NTRK-mutant ER-negative, HER2-low recurrent mBC receives trastuzumab deruxtecan — Lai (Amber) Xu, MD, PhD (21:07) Case: A woman in her mid 70s with PIK3CA-mutant recurrent metastatic triple-negative breast cancer who developed a diverticular abscess on neoadjuvant chemoimmunotherapy receives sacituzumab govitecan and pembrolizumab — Alan B Astrow, MD (31:49) Case: A woman in her mid 60s with ER-negative, HER2-low mBC receives sacituzumab govitecan after experiencing disease progression on capecitabine — Laila Agrawal, MD (38:37) Case: A woman in her late 50s with ER-negative, HER2-low mBC receives trastuzumab deruxtecan after experiencing disease progression on sacituzumab govitecan — Kimberly Ku, MD (44:24) Case: A woman in her early 60s with ER-positive, HER2-low mBC and hyperglycemia receives trastuzumab deruxtecan after experiencing disease progression on capivasertib/fulvestrant — Eleonora Teplinsky, MD (48:50) CME information and select publications

Send us a textIn this episode of Medical Money Matters, we sit down with Jon Anderson, AIA, NCARB, AIBC of Anderson Dabrowski to explore the art and science of clinical space design. From timing and budgeting to layout efficiencies and flexible use of space, Jon shares key insights that can transform how medical spaces function—for patients, providers, and staff alike. Whether you're building new or renovating old, this conversation is packed with practical pearls to help you create environments that truly support better care. Jon can be reached at: janderson@adarchitects.com or via LinkedIn here: https://www.linkedin.com/in/jon-anderson-aia-ncarb-aibc-78578014/. His website is here: https://www.adarchitects.com/Please Follow or Subscribe to get new episodes delivered to you as soon as they drop! Visit Jill's company, Health e Practices' website: https://healtheps.com/ Subscribe to our newsletter, Health e Connections: http://21978609.hs-sites.com/newletter-subscriber Want more formal learning? Check out Jill's newly released course: Physician's Edge: Mastering Business & Finance in Your Medical Practice. 32.5 hours of online, on-demand CME-accredited training tailored just for busy physicians. Find it here: https://healtheps.com/physicians-edge-mastering-business-finance-in-your-medical-practice/ Purchase your copy of Jill's book here: Physician Heal Thy Financial Self Join our Medical Money Matters Facebook Group here: https://www.facebook.com/groups/3834886643404507/ Original Musical Score by: Craig Addy at https://www.underthepiano.ca/ Visit Craig's website to book your Once in a Lifetime music experience Podcast coaching and development by: Jennifer Furlong, CEO, Communication Twenty-Four Seven https://www.communicationtwentyfourseven.com/

Dr Aditya Bardia and Dr Adam M Brufsky discuss published and emerging datasets investigating the incorporation of antibody-drug conjugates into the treatment of metastatic breast cancer.CME information and select publications here.

In this episode of Bowel Sounds, hosts Dr. Peter Lu and Dr. Jenn Lee talk to Dr. Kevin Watson, pediatric gastroenterologist and Assistant Director of Clinical Informatics at Akron Children's Hospital and Associate Professor at Northeastern Ohio Medical University. We talk about the use of AI-powered ambient listening technology for clinical documentation and his experience introducing AI scribes to his hospital.Learning objectivesUnderstand the advantages and limitations of the current state of ambient listening technology for clinical documentation.Review practical guidance on usage of this technology in pediatric gastroenterology.Recognize key strategies for successful implementation and adoption of this technology.Support the showThis episode may be eligible for CME credit! Once you have listened to the episode, click this link to claim your credit. Credit is available to NASPGHAN members (if you are not a member, you should probably sign up). And thank you to the NASPGHAN Professional Education Committee for their review!As always, the discussion, views, and recommendations in this podcast are the sole responsibility of the hosts and guests and are subject to change over time with advances in the field.Check out our merch website!Follow us on Bluesky, Twitter, Facebook and Instagram for all the latest news and upcoming episodes.Click here to support the show.

Welcome to The Chrisman Commentary, your go-to daily mortgage news podcast, where industry insights meet expert analysis. Hosted by Robbie Chrisman, this podcast delivers the latest updates on mortgage rates, capital markets, and the forces shaping the housing finance landscape. Whether you're a seasoned professional or just looking to stay informed, you'll get clear, concise breakdowns of market trends and economic shifts that impact the mortgage world.In today's episode, we review just what people are talking about in the halls of MBA Annual. Plus, Robbie sits down with Geoff Sharp at Eris Innovations, the creators of CME's Eris SOFR Swap futures, to discuss on the growing need for SOFR-based cash flow hedging solutions. And we close by looking at what economic releases are due out this week despite the government shutdown.Today's podcast is brought to you by nCino, makers of the nCino Mortgage Suite for the modern mortgage lender. nCino Mortgage Suite's three core products -- nCino Mortgage, nCino Incentive Compensation, and nCino Mortgage Analytics -- unite the people, systems, and stages of the mortgage process into a seamless end-to-end solution embedded with data-driven insights and intelligent automation. See how nCino can support a homeownership journey that your borrowers and your team will love at nCino.com.

Featuring perspectives from Dr Carla Casulo and Dr Brad S Kahl: Introduction (0:00) Faculty Data and Case Presentation — Dr Kahl (6:38) Faculty Data and Case Presentation — Dr Casulo (25:38) CME information and select publications

There is so much noise today when it comes to nutrition. How do we know which voices to listen to? How do we know what is truly evidence-based versus bogus fads? And most importantly, how do we address nutrition with patients?Do you know what to say when a patient asks you which diet is better - carnivore or paleo? How do you support a patient in their weight loss goals with appropriate language that encourages and educates, not demeans and defeats?My dear friend Colleen Sloan is back on the podcast today to answer all these questions and more. Colleen is a Registered Dietician turned Pediatric PA who recently launched the Obesity Medicine Nutrition Course. Her course is designed for clinicians and dieticians who treat obesity in patients of any age. The course is an all inclusive, comprehensive nutrition program that includes 13 self-paced modules taught by Colleen and 11 industry-leading experts. The course also includes a Resource Vault and online community. In addition to receiving a clear roadmap on how to successfully discuss and treat obesity, you also earn 10.5 CME credits!Tune into today's episode to learn more about the Obesity Medicine Nutrition Course as well as actionable tips you can use in clinic today when discussing obesity and nutrition with your patients. Obesity Medicine Nutrition Course (use code TRACY10 for 10% off): https://www.examroomnutrition.com/a/2148137603/dcrdFWdoSPONSORS